Avenue Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OID
Avenue Therapeutics reports its 10-K filing for FY 2024, highlighting a delisting notice from Nasdaq and an ongoing dispute with AnnJi over the AJ201 license agreement.
OID
10-K: Avenue Therapeutics Details Capital Structure, Voting Rights, and Warrant Information in SEC Filing
Avenue Therapeutics' 10-K filing provides a comprehensive overview of its capital stock, including common stock, preferred stock, and various warrants, along with their associated rights and terms.